Laryngeal cancer diagnosis and treatment statistics

Surgery Rate

Head and neck cancer patients receiving major surgical resection, 2006-2010, England

 

Patient Experience

Head and neck cancer patients rating their care very good or excellent, 2014, England

'14-day / Two-week wait'

England meets the standard for their country on the percentage of patients first seen by a specialist within two weeks of urgent GP referral for suspected cancer.[1]

'Two-week wait' supports early diagnosis as spotting cancer early is important for improving survival, so it is important that patients with potential cancer symptoms are referred promptly.

'31-day wait'

Scotland and Northern Ireland meet the standard for their country on the percentage of patients that receive their first cancer treatment within 31 days of a decision to treat, while Wales does not meet the standard for their country.[2-4]

The speed at which patients receive their first treatment can have a positive outcome on their clinical outcome, so it is important that patients with cancer symptoms are treated promptly.

'62-day wait'

Wales, Scotland and Northern Ireland do not meet the standard for their country on the percentage of patients receiving their first definitive treatment for cancer within two months of a GP referral for suspected cancer.[2-4]

The speed at which patients receive their first treatment can have a positive outcome on their clinical outcome, so it is important that patients with cancer symptoms are treated promptly.

Cancer waiting times coding and standards are different in each country and so comparisons should not be made between countries, only each country against their own measures.

Head and Neck Cancers, Waiting Times, UK countries, 2014-15

    England Wales Scotland Northern Ireland
'14-day wait': seen by specialist following referral Performance 95.7%      
Standard 93%      
Performance against standard Meets standard      
'31-day wait': receipt of first treatment following decision to treat Performance   97.2% 96.0% 96.4%
Standard   98% 95% 98%
Performance against standard   Does not meet standard Meets standard Does not meet standard
'62-day wait': receipt of first treatment following referral Performance   74.5% 89.7% 60.0%
Standard   95%> 95% 95%
Performance against standard   Does not meet standard Does not meet standard Does not meet standard

Data not available for '14-day wait' in Wales, Scotland or NI.
Data not available for '31- or 62-day wait' in England.

References

  1. NHS England. Cancer waiting times(link is external).  Accessed May 2015.
  2. StatsWales. Cancer waiting times(link is external). Accessed May 2015.
  3. ISD Scotland. Cancer Waiting Times(link is external). Accessed June 2015.
  4. Department of Health, Social Services and Public Safety. Cancer Waiting Times(link is external). Accessed June 2015
Last reviewed:

Between 32% and 75% of patients diagnosed with head and neck cancer in England during 2013-2014 had surgery to remove their tumour, as part of their primary cancer treatment.[1] This includes patients who had surgery alone, and those who also had other treatments such as radiotherapy or chemotherapy. Surgery not intending to remove the tumour, including biopsies or other palliative surgery, is not included in this figure.

The proportion of head and neck cancer patients having surgery to remove their primary tumour is strongly influenced by stage at diagnosis.

Other factors are also important, such as whether the patient is generally well enough to tolerate the treatment, the patient’s age, and their own treatment preference.

Head and Neck Cancers (C01-04, C06-10, C12, C13, C32) Percentage of Patients Having Surgery to Remove Their Tumour Part of Their Primary Treatment, Persons, All ages, England, 2013-2014

Stage at diagnosis Percentage of Hypopharynx patients (C12-13) Percentage of Larynx patients (C32) Percentage of Oral cavity patients (C02-04, C06) Percentage of Oropharynx patients (C01,09-10) Percentage of Salivary gland patients (C07-08)
All stages combined 32.1% 46.4% 74.6% 40.5% 74.1%
Stage 1 53.8% 55% 94.3% 60.7% 94%
Stage 2 14.5% 28.6% 86.3% 49.4% 92.4%
Stage 3 21.1% 42.6% 81.6% 41.9% 82.4%
Stage 4 36.9% 55.2% 62.1% 39.8% 67.8%
Unknown stage 26.3% 41.6% 60.8% 35.2% 65%

References

  1. National Cancer Registration & Analysis Service and Cancer Research UK: "Chemotherapy, Radiotherapy and Tumour Resections in England: 2013-2014" workbook. London: NCRAS; 2017.

About this data

Data is for: England, 2013-2014

Head and neck site ICD10 Code Surgery is included if it occurred within the following months after diagnosis
Hypopharynx C12, C13 12
Larynx C32 12
Oral cavity C02 - 04, C06 6
Oropharynx C01, C09 - 10 12
Salivary glands C07, C08 6

Surgery to remove the tumour includes any surgical attempt to remove the whole of the primary tumour within the number of months after diagnosis as shown in the table above.

The percentage of patients having surgery to remove their tumour do not sum to 100%, as patients are able to have more than one type of treatment, as well as other treatments not included in this data, for example hormonal therapy.

Last reviewed:

Between 43% and 85% of patients diagnosed with head and neck cancer in England during 2013-2014 had curative or palliative radiotherapy, as part of their primary cancer treatment.[1] This includes patients who had radiotherapy alone, and those who also had other treatments such as surgery to remove the tumour, or chemotherapy.

The proportion of head and neck cancer patients having radiotherapy is strongly influenced by stage at diagnosis. 

Other factors are also important, such as whether the patient is generally well enough to tolerate the treatment, the patient’s age, and their own treatment preference.

Head and Neck Cancers (C01-04, C06-10, C12, C13, C32) Percentage of Patients Receiving Radiotherapy as Part of Their Primary Treatment, Persons, All ages, England, 2013-2014

Stage at diagnosis Percentage of Hypopharynx patients (C12-13) Percentage of Larynx patients (C32) Percentage of Oral cavity patients (C02-04, C06) Percentage of Oropharynx patients (C01,09-10) Percentage of Salivary gland patients (C07-08)
All stages combined 71.4% 64.1% 42.4% 84.6% 56.1%
Stage 1 53.8% 53.9% 10.8% 64.1% 26.5%
Stage 2 82.6% 86.6% 34.7% 83.4% 59.2%
Stage 3 79.7% 80.2% 59.9% 87.7% 73.6%
Stage 4 72.7% 66.5% 70.3% 89.1% 79.5%
Unknown stage 57.2% 49.9% 28.9% 70.2% 46.3%

References

  1. National Cancer Registration & Analysis Service and Cancer Research UK: "Chemotherapy, Radiotherapy and Tumour Resections in England: 2013-2014" workbook. London: NCRAS; 2017.

About this data

Data is for: England, 2013-2014
Head and neck site ICD10 Code Radiotherapy is included within the following months after diagnosis
Hypopharynx C12, C13 6
Larynx C32 6
Oral cavity C02 - 04, C06 15
Oropharynx C01, C09 - 10 6
Salivary glands C07, C08 9

Radiotherapy includes both curative and palliative teletherapy procedures (excluding Brachytherapy and Contact Radiotherapy) within the number of months after diagnosis as shown in the table above.

The percentage of patients having radiotherapy do not sum to 100%, as patients are able to have more than one type of treatment, as well as other treatments not included in this data, for example hormonal therapy.

Last reviewed:

Between 8% and 61% of patients diagnosed with head and neck cancer in England in 2013-2014 had curative or palliative chemotherapy, as part of their primary cancer treatment.[1] This includes patients who had chemotherapy alone, and those who also had other treatments such as tumour removal surgery or radiotherapy.
The proportion of head and neck cancer patients having chemotherapy is strongly influenced by stage at diagnosis. 

Other factors are also important, such as whether the patient is generally well enough to tolerate the treatment, the patient’s age, and their own treatment preference.

Head and Neck cancers (C01-04, C06-10, C12, C13, C32) Percentage of Patients Receiving Chemotherapy as Part of Their Primary Treatment, Persons, Aged All ages, England, 2013-2014

Stage at diagnosis Percentage of Hypopharynx patients (C12-13) Percentage of Larynx patients (C32) Percentage of Oral cavity patients (C02-04, C06) Percentage of Oropharynx patients (C01,09-10) Percentage of Salivary gland patients (C07-08)
All stages combined 39.9% 17.7% 18% 61.3% 7.6%
Stage 1 15.4% 2.4% 4.3% 17.9% 0.7%
Stage 2  31.9% 8.4% 8.8% 26.9% 3.8%
Stage 3 42.2% 40.7% 22.2% 59.1% 6.6%
Stage 4 43.5% 36% 32.5% 70.5% 14.8%
Unknown stage 30.9% 10.4% 12.3% 48.5% 6.4%

References

  1. National Cancer Registration & Analysis Service and Cancer Research UK: "Chemotherapy, Radiotherapy and Tumour Resections in England: 2013-2014" workbook. London: NCRAS; 2017

About this data

Data is for: England, 2013-2014

Head and Neck site ICD10 Code Chemotherapy is included within the following months after diagnosis
Hypopharynx C12, C13 6
Larynx C32 15
Oral cavity C02 - 04, C06 18
Oropharynx C01, C09 - 10 6
Salivary glands C07, C08 15

Chemotherapy includes both curative and palliative chemotherapy (excluding Hormonal therapy, and other supportive drugs such as Zoledronic acid, Pamidronate, Denosumab) within the number of months after diagnosis as shown in the table above.

The percentage of patients having chemotherapy do not sum to 100%, as patients are able to have more than one type of treatment, as well as other treatments not included in this data, for example hormonal therapy.

Last reviewed:

90-92% of head and neck cancer patients rate their care as ‘excellent’ or ‘very good’.[1] Patient experience varies with individual needs and concerns, which are influenced by many aspects of personal background, disease characteristics and the care environment.

83-85% of patients were given the name of a Clinical Nurse Specialist in charge of their care.[1] Being given the name of a Clinical Nurse Specialist in charge of a patients’ care is the factor most likely to be associated with high patient satisfaction scores.[2]

50-59% said they saw their GP once or twice before being told they had to go to hospital.[1] How often a patient sees their GP before being referred to hospital varies by cancer type depending on ease of diagnosis.[3]

For oral cancer the proportion of patients that said they saw their GP once or twice before being told they had to go to hospital is similar to the average for all cancer patients, for laryngeal cancer the proportion is lower than the average for all cancer patients.[1]

Spotting cancer early is important for improving survival so it is important that patients with potential cancer symptoms are referred for tests promptly.

Oral Cancer (C00-C06,C09-C10,C12-C14), Patient Experience Survey, by Sex, England, 2014

Female Male Persons
Percentage of patients treated for cancer who visited their GP once or twice about the health problem caused by their cancer 65.3% 56.4% 59.2%
Percentage of patients treated for cancer who said they were given the name of a Clinical Nurse Specialist in charge of their care 82.1% 86.2% 84.9%
Percentage of patients treated for cancer who rated their overall care as excellent or very good 90.8% 92.2% 91.8%

Laryngeal cancer (C32), Patient Experience Survey, by Sex, England, 2014

Female Male Persons
Percentage of patients treated for cancer who visited their GP once or twice about the health problem caused by their cancer 47.1% 51.0% 50.3%
Percentage of patients treated for cancer who said they were given the name of a Clinical Nurse Specialist in charge of their care 89.8% 81.2% 82.5%
Percentage of patients treated for cancer who rated their overall care as excellent or very good 91.8% 89.4% 89.8%

About this data

Data is for England, 2014, Head and Neck cancer, ICD-10 codes (C00-C06,C09-C10,C12-C14, C32)

Patient Experience data is for adult patients in England with a primary diagnosis of cancer and who had been in active treatment between September and November 2013 who completed a survey in 2014.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 1.7 out of 5 based on 7 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page